PR
ProQR Therapeutics N.V.
PRQR · NASDAQ
$1.86 +1.92% (+$0.04)
1M -24.69%
Market Cap 170.8M €
P/E Ratio -
Div. Yield -
ROE 68.44%
Piotroski F-Score Weak
1/9Valuation
42 /100
Fair P/B 2.15x
P/S 9.20x
EV/FFO N/A
Growth
78 /100
Growing Book val. growth 9.72%
Rev. growth 61.99%
FCF growth N/A
Profitability
20 /100
Weak Net margin 228.29%
Op. margin 232.71%
FCF margin 270.78%
Quality
2 /100
Poor ROE 68.44%
ROA 31.76%
Asset turnover 0.14x
Debt
100 /100
Low Current ratio 3.49x
Debt/Equity 0.17x
Net debt/EBITDA N/A
Stability
16 /100
Unstable Rev. volatility 104.73%
EPS volatility 38.80%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRQR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel Anton de Boer
Employees
166
Headquarters
Leiden
Upcoming events
05 NOV
Earnings
Upcoming earnings report